Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug 5:9:4303-18.
doi: 10.2147/DDDT.S86105. eCollection 2015.

The role of taxanes in triple-negative breast cancer: literature review

Giorgio Mustacchi  1 , Michelino De Laurentiis  2
Affiliations
Review

The role of taxanes in triple-negative breast cancer: literature review

Giorgio Mustacchi et al. Drug Des Devel Ther. .

Erratum in

Abstract

Breast cancer (BC) is the most frequent tumor worldwide. Triple-negative BCs are characterized by the negative estrogen and progesterone receptors and negative HER2, and represent 15% of all BCs. In this review, data on the use of taxanes in triple-negative BCs are analyzed, concluding they are effective in any clinical setting (neoadjuvant, adjuvant, and metastatic). Further, the role of nab-paclitaxel (formulation of albumin-bound paclitaxel) in these tumors is also evaluated. The available data show the clinical potential of nab-paclitaxel based combinations in terms of long-duration response, increased survival, and better quality of life of patients with triple-negative metastatic BC. The ongoing trials will give further information on the better management of this type of tumor.

Keywords: bevacizumab; docetaxel; nab-paclitaxel; paclitaxel.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of neoadjuvant chemotherapy in data of triple-negative BCs vs non-triple-negative BCs. Notes: aP=0.034; bP=0.0001; cP=0.007. Abbreviations: Anthra, anthracycline; OS, overall survival; Other, non-triple-negative tumors; pCR, pathological complete response; PFS, progression-free survival.
Figure 2
Figure 2
Efficacy parameters in patients with triple-negative BC treated with nab-paclitaxel/bevacizumab/carboplatin. Notes: CBR: 95% CI 80–99. ORR: 95% CI 69–95. Abbreviations: BC, breast cancer; CBR, clinical benefit rate; CI, confidence interval; CR, complete response; ORR, overall response rate; PR, partial response; SD, stable disease.
Figure 3
Figure 3
Pathological Response rate in patients treated with conventional paclitaxel or nab-paclitaxel. Notes: ypT0ypN0: absence of tumor cells in Tumor and Nodes. ypT0/ispN0: absence of tumor cells in Tumor and Nodes, but in situ cancer cells in the tumor allowed. ypT0/isypN0/+: Absence of tumor cells in Tumor and Nodes, but positive Nodes also allowed. Abbreviation: pCR, pathological complete response.
See this image and copyright information in PMC

References

    1. Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E, ESMO Guidelines Working Group Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii11–vii19. - PubMed
    1. AIOM-AIRTUM . I Numeri del Cancro in Italia. 2014 [The numbers of cancer in Italy. 2014] AIOM-AIRTUM; Milan: Associazione Italiana di Oncologia Medica; 2014. [Accessed July 4, 2015]. Available from: http://www.aiom.it/area+pubblica/area+medica/pubblicazioni/1,332,1. Italian.
    1. de Rujters TC, Veeck J, de Hoon JPJ, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 2011;137:183–192. - PMC - PubMed
    1. Chacón RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res. 2010;12(Suppl 2):S3. - PMC - PubMed
    1. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011;16(Suppl 1):S1–S11. - PubMed

MeSH terms